Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech reaffirms its strategic focus on global licensing partnerships to address the growing BPH market. The company highlights that the global BPH patient population reached 112.5 million in 2021 and is projected to grow to 150-156 million by 2035, with the market size expected to grow from $13 billion in 2025 to $22-22.6 billion by 2035. Jyong Biotech's lead candidate Botreso® (API-1) has completed four Phase III clinical trials and aims to address unmet medical needs caused by severe side effects of existing treatments.